MARKET

NVIV

NVIV

InVivo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.060
-0.070
-6.19%
Pre Market: 1.010 -0.05 -4.72% 05:27 03/04 EST
OPEN
1.170
PREV CLOSE
1.130
HIGH
1.170
LOW
1.030
VOLUME
3.04K
TURNOVER
--
52 WEEK HIGH
5.83
52 WEEK LOW
0.4975
MARKET CAP
22.44M
P/E (TTM)
-0.0910
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
10-K: INVIVO THERAPEUTICS HOLDINGS CORP.
(EDGAR Online via COMTEX) -- Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion should be...
Edgar Online - (EDG = 10Q, 10K) · 2d ago
5 Penny Stocks To Watch This Week If Biotech Is Your Focus In February
Penny Stocks · 02/24 21:12
4 Penny Stocks to Watch For The 2nd Half of February
Penny Stocks · 02/24 21:11
Making A List Of Penny Stocks To Watch? 3 Turning Heads In February
Penny Stocks · 02/24 21:11
InVivo is up after peer-reviewed publication of study on spinal cord injury
InVivo Therapeutics ([[NVIV]] +5.4%) is trading higher today in above-average volume after the company announced the publication of a peer-reviewed manuscript describing the complete six-month primary endpoint results from its single-arm INSPIRE
Seekingalpha · 02/16 19:53
Study Of InVivo Therapeutics' Inspire 1.0 Says '...implantation of the NSS within the spinal cord appeared to be safe in the setting of surgical decompression and stabilization for complete (AIS grade A) thoracic SCI.'
https://thejns.org/spine/view/journals/j-neurosurg-spine/aop/article-10.3171-2020.8.SPINE191507/article-10.3171-2020.8.SPINE191507.xml
Benzinga · 02/16 13:26
InVivo Therapeutics Highlights Publication In Peer-Reviewed Journal Of Neurosurgery: Spine; Says Manuscript Details Complete Six-Month Inspire 1.0 Primary Endpoint Study Results
InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine Manuscript Details Complete Six-Month INSPIRE 1.0 Primary Endpoint Study Results InVivo Therapeutics Holdings Corp.
Benzinga · 02/16 13:22
InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing the previously presented complete six-month primary endpoint results from the company's ...
Business Wire · 02/16 13:00
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVIV. Analyze the recent business situations of InVivo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS
Institutional Holdings
Institutions: 38
Institutional Holdings: 472.28K
% Owned: 2.23%
Shares Outstanding: 21.17M
TypeInstitutionsShares
Increased
2
7.36K
New
6
178.93K
Decreased
3
6.33K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-2.96%
Healthcare Equipment & Supplies
-2.63%
Key Executives
Non-Executive Chairman/Independent Director
Ann Merrifield
Non-Executive Chairman/Independent Director
C. Ann Merrifield
President/Chief Executive Officer/Director
Richard Toselli
Chief Financial Officer/Chief Accounting Officer
Jeff Modestino
Chief Financial Officer
Richard Christopher
Independent Director
Daniel Marshak
Independent Director
Christina Morrison
Independent Director
Richard Roberts
Independent Director
Robert Rosenthal
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About NVIV
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Webull offers kinds of Invivo Therapeutics Holdings Corp stock information, including NASDAQ:NVIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVIV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVIV stock methods without spending real money on the virtual paper trading platform.